Allergan PLC is the latest firm targeted by the US Department of Justice in its investigation of price hikes in the generic drug industry.
The company reported in its Aug. 6 quarterly SEC filing that on June 25, Actavis (renamed Allergan following the merger...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?